FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2214712710> ?p ?o ?g. }

• W2214712710 abstract "5140 Background: PSA and ALK are recognized factors for predicting survival in men with metastatic HRPC. However, few studies have evaluated the combined effects of PSA and ALK on survival of patients with metastatic HRPC. Methods: 224 patients treated with chemotherapy for bone metastatic HRPC between 1999 and 2006 were identified from an institutional database. 143 patients had ALK as well as PSA values at start of chemotherapy. There were no statistically significant differences in baseline characteristics (including age, Gleason score, PSA, clinical stage at diagnosis or at the initiation of chemotherapy) between groups with and without available ALK (p>0.05). The primary endpoint was overall survival (OS) after chemotherapy. ALK was dichotomized to normal and abnormal groups based on institutional normal range (38–126 U/L). The effect of PSA was evaluated both as categorical (low, median and high group using the 33%, 66% cut-off values) and continuous values with log transformation in Cox regression. Results: Of 143 eligible patients, median ALK was 159 U/L (range: 52–2,020 U/L); 89 (62%) had elevated ALK. Median PSA at start of chemotherapy was 147 ng/mL; 93 ng/mL in patients with normal ALK and 171 ng/mL in those with elevated ALK. With median follow-up of 30 months after chemotherapy, 93 patients have died. Median OS after chemotherapy was 15.8 (range 0–57) months and was significantly longer if ALK was in the normal range (21.3 vs. 14 months, p=0.005). For the group with normal ALK, median OS was 12.5, 24.5 and 36.9 months for patients with low, median and high PSA, respectively; while there was no effect of PSA on survival if ALK was beyond the normal range (16.5 vs. 11.9 vs. 12.1 months) (p=0.21 for the interaction). In multivariable analysis after adjusting for age, the interaction effect of PSA and ALK on OS was statistically significant (p=0.02). The relative risk due to one unit increase in the value of Ln(PSA) was 0.68 (95% CI: 0.51–0.92) if ALK in the normal range, compared to 1.07 (95% CI: 0.85–1.35) in the group with elevated ALK. Conclusions: ALK was a significant factor in predicting OS for men with bone metastatic HRPC. In patients with normal ALK, a higher PSA was associated with improved survival. No significant financial relationships to disclose." @default.
• W2214712710 created "2016-06-24" @default.
• W2214712710 creator A5017334876 @default.
• W2214712710 creator A5018292930 @default.
• W2214712710 creator A5048151721 @default.
• W2214712710 creator A5066816851 @default.
• W2214712710 date "2007-06-20" @default.
• W2214712710 modified "2023-09-25" @default.
• W2214712710 title "Correlation of prostate-specific antigen (PSA) levels and survival in men with bone metastatic hormone-refractory prostate cancer (HRPC) and normal alkaline phosphatase (ALK)" @default.
• W2214712710 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.5140" @default.
• W2214712710 hasPublicationYear "2007" @default.
• W2214712710 type Work @default.
• W2214712710 sameAs 2214712710 @default.
• W2214712710 citedByCount "0" @default.
• W2214712710 crossrefType "journal-article" @default.
• W2214712710 hasAuthorship W2214712710A5017334876 @default.
• W2214712710 hasAuthorship W2214712710A5018292930 @default.
• W2214712710 hasAuthorship W2214712710A5048151721 @default.
• W2214712710 hasAuthorship W2214712710A5066816851 @default.
• W2214712710 hasConcept C121608353 @default.
• W2214712710 hasConcept C126322002 @default.
• W2214712710 hasConcept C143998085 @default.
• W2214712710 hasConcept C147483822 @default.
• W2214712710 hasConcept C160160445 @default.
• W2214712710 hasConcept C181199279 @default.
• W2214712710 hasConcept C203014093 @default.
• W2214712710 hasConcept C2776235491 @default.
• W2214712710 hasConcept C2780192828 @default.
• W2214712710 hasConcept C2781406297 @default.
• W2214712710 hasConcept C3019894029 @default.
• W2214712710 hasConcept C55493867 @default.
• W2214712710 hasConcept C71924100 @default.
• W2214712710 hasConcept C86803240 @default.
• W2214712710 hasConceptScore W2214712710C121608353 @default.
• W2214712710 hasConceptScore W2214712710C126322002 @default.
• W2214712710 hasConceptScore W2214712710C143998085 @default.
• W2214712710 hasConceptScore W2214712710C147483822 @default.
• W2214712710 hasConceptScore W2214712710C160160445 @default.
• W2214712710 hasConceptScore W2214712710C181199279 @default.
• W2214712710 hasConceptScore W2214712710C203014093 @default.
• W2214712710 hasConceptScore W2214712710C2776235491 @default.
• W2214712710 hasConceptScore W2214712710C2780192828 @default.
• W2214712710 hasConceptScore W2214712710C2781406297 @default.
• W2214712710 hasConceptScore W2214712710C3019894029 @default.
• W2214712710 hasConceptScore W2214712710C55493867 @default.
• W2214712710 hasConceptScore W2214712710C71924100 @default.
• W2214712710 hasConceptScore W2214712710C86803240 @default.
• W2214712710 hasLocation W22147127101 @default.
• W2214712710 hasOpenAccess W2214712710 @default.
• W2214712710 hasPrimaryLocation W22147127101 @default.
• W2214712710 hasRelatedWork W1980188241 @default.
• W2214712710 hasRelatedWork W2008116325 @default.
• W2214712710 hasRelatedWork W2055393917 @default.
• W2214712710 hasRelatedWork W2059622952 @default.
• W2214712710 hasRelatedWork W2074491453 @default.
• W2214712710 hasRelatedWork W2152050874 @default.
• W2214712710 hasRelatedWork W2156659229 @default.
• W2214712710 hasRelatedWork W2691127072 @default.
• W2214712710 hasRelatedWork W2808552915 @default.
• W2214712710 hasRelatedWork W3139593660 @default.
• W2214712710 isParatext "false" @default.
• W2214712710 isRetracted "false" @default.
• W2214712710 magId "2214712710" @default.
• W2214712710 workType "article" @default.